Cerebrolysin, solution for injection 5ml ampoules 5pcs

Composition

>

1 ml of solution for injection contains:

Active ingredient:

cerebrolysin concentrate (complex of peptides derived from pig brain) 215.2 mg,

excipients:

sodium hydroxide;

water for injection

Pharmacological action

Cerebrolysin has a positive effect on cognitive impairment, memory processes.

Indications

• chronic cerebrovascular insufficiency;
• ischemic stroke;
• Alzheimer’s disease;
• dementia syndrome of various origins;
• traumatic brain and spinal cord injuries;
• mental retardation in children;
• hyperactivity and attention deficit in children;
• in complex therapy for endogenous depression resistant to antidepressants.

Use during pregnancy and lactation

With caution, the drug is prescribed in the first trimester of pregnancy and during lactation.

During pregnancy and lactation, Cerebrolysin should be used only after careful analysis of the ratio of the positive effect of treatment and the risk associated with its implementation.

The results of experimental studies do not give grounds to believe that Cerebrolysin has a teratogenic effect or has a toxic effect on the fetus.

However, no similar clinical trials have been conducted.

Contraindications

• acute renal failure;
• individual drug intolerance;
• epileptic status.

Side effects

From the gastrointestinal tract: rarely – loss of appetite, dyspepsia, diarrhea, constipation, nausea and vomiting.

From the central nervous system and peripheral nervous system: in rare cases, the intended activation effect was accompanied by arousal (manifested by aggressive behavior, confusion, insomnia). There are reports of occurrence in isolated cases (

Immune system disorders: extremely rare-hypersensitivity reactions or allergic reactions, manifested by headache, pain in the neck, limbs, lower back, shortness of breath, chills and collaptoid state.

Reaction to use: with excessively rapid use, in rare cases, a feeling of heat, sweating, dizziness may occur; in isolated cases, rapid heartbeat or arrhythmias. Therefore, the drug should be administered slowly.

Local reactions: rarely-redness of the skin, itching and burning at the injection site.

Other: extremely rare-studies have reported cases of hyperventilation, hypertension, hypotension, fatigue, tremor, depression, apathy, dizziness, and flu-like symptoms (cough, runny nose, and respiratory tract infections).

It should be noted that some undesirable effects (agitation, arterial hypertension, arterial hypotension, lethargy, tremor, depression, apathy, dizziness, headache, shortness of breath, diarrhea, nausea) were detected during clinical trials and occurred equally in patients treated with Cerebrolysin and in patients in the placebo group.

Interaction

Taking into account the pharmacological profile of the drug Cerebrolysin, special attention should be paid to possible additive effects when co-administered with antidepressants, including MAO inhibitors. In such cases, it is recommended to reduce the dose of an antidepressant.

Do not mix Cerebrolysin and balanced amino acid solutions in the same infusion solution.

Cerebrolysin is incompatible with solutions containing lipids and with solutions that change the pH of the medium [5-8].

How to take, course of use and dosage

Intramuscularly (up to 5 ml), intravenously (up to 10 ml), intravenously, by slow infusion (from 10 to 50 ml).

The dose and duration of treatment depend on the nature and severity of the disease, as well as on the age of the patient. It is possible to prescribe single doses, the value of which can reach 50 ml, but it is more preferable to conduct a course of treatment. The recommended optimal course of treatment is daily injections for 10-20 days.

Acute conditions (ischemic stroke, TBI, complications after neurosurgical operations) — from 10 to 50 ml.

The residual period of cerebral stroke and traumatic brain and spinal cord injury is from 5 to 50 ml.

Psychoorganic syndrome and depression — from 5 to 30 ml.

Alzheimer’s disease, dementia of vascular and combined Alzheimer’s-vascular genesis-from 5 to 30 ml.

In neuropediatric practice-0.1-0.2 ml/kg —

To increase the effectiveness of treatment, repeated courses can be performed, as long as the patient’s condition improves due to treatment. After the first course, the frequency of prescribing doses can be reduced to 2 or 3 times a week.

Doses from 10 to 50 ml are recommended to be administered only by slow intravenous infusions after dilution with the proposed standard infusion solutions. The duration of infusions is from 15 to 60 minutes.

Special instructions

The compatibility of the drug (within 24 hours at room temperature and in the presence of lighting) with the following standard solutions for infusions was checked and confirmed:

– 0.9% sodium chloride solution (9 mg NaCl / ml);

– Ringer’s solution (Na+ – 153.98 mmol/l; Ca2+ – 2.74 mmol/l; K+ – 4.02 mmol/l; Cl – – 163.48 mmol/l).

– 5% glucose solution.

Concomitant use of the drug Cerebrolysin with vitamins and drugs that improve heart circulation is allowed, but these drugs should not be mixed in the same syringe with the drug Cerebrolysin. Use only a clear solution and only once.

Influence on the ability to drive vehicles and work with mechanisms. Clinical trials have shown that Cerebrolysin has no effect on the ability to drive vehicles and use mechanisms.

Form of production

Solution for injection

Storage conditions

In a dark place, at a temperature not exceeding 25 °C

Shelf life

5 years

Active ingredient

Brain Peptide Complex

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection